1-磷酸鞘氨醇在缺血性卒中中的作用研究进展

doi:10.3969/j.issn.1673-5765.2023.07.014

摘要/Abstract

摘要： 脑组织缺血坏死后释放出炎性因子诱发炎症反应，并激活神经胶质细胞参与损伤后的级联免疫反应，1-磷酸鞘氨醇（sphingosine 1-phosphate，S1P）代谢与缺血性卒中具有相关性，神经胶质细胞在炎症状态下上调1-磷酸鞘氨醇受体（sphingosine 1-phosphate receptors，S1PRs）的表达，S1PRs发出S1P信号参与脑组织中炎症介质的上调，S1P与S1PRs结合参与缺血性卒中后炎症和免疫反应、内皮细胞的黏附和血管生成以及改善血脑屏障功能。本文就S1P的代谢和生理功能及其与S1PRs结合后改善缺血性卒中的潜在机制进行综述，以期为寻找缺血性卒中相关药物新靶点提供依据。

文章导读：

S1P与不同 S1PRs 结合，并通过不同信号通路发挥作用，表现出对缺血性卒中的致病作用或治疗潜力，使S1PRs 成为治疗缺血性卒中的潜在靶点。

关键词: 1-磷酸鞘氨醇; 缺血性卒中; 鞘氨醇; 卒中

Abstract: After cerebral ischemia and necrosis, inflammatory factors are released to induce inflammatory response, and glial cells are activated to participate in the cascade immune response after ischemia injury. The metabolism of sphingosine 1-phosphate (S1P) is correlated with ischemic stroke. Glial cells up-regulate the expression of sphingosine 1-phosphate receptors (S1PRs) in the inflammatory state. S1PRs sends S1P signal to participate in the up-regulation of inflammatory mediators in the brain tissue. The combination of S1P and S1PRs is involved in the inflammatory and immune response after ischemic stroke, endothelial cell adhesion and angiogenesis, and the improvement of blood-brain barrier function. This article reviews the metabolic and physiological functions of S1P and its potential mechanism of improving ischemic stroke after binding to S1PRs, in order to provide a strong evidence for finding new drug targets related to ischemic stroke.

Key words: Sphingosine 1-phosphate; Ischemic stroke; Sphingosine; Stroke

李萍, 付胜奇. 1-磷酸鞘氨醇在缺血性卒中中的作用研究进展[J]. 中国卒中杂志, 2023, 18(07): 829-836.

LI Ping, FU Shengqi. Research Progress on the Role of Sphingosine 1-Phosphate in Ischemic Stroke[J]. Chinese Journal of Stroke, 2023, 18(07): 829-836.

参考文献

[1] FESKE S K. Ischemic stroke[J]. Am J Med，2021，134（12）：1457-1464.
[2] SHI K，TIAN D C，LI Z G，et al. Global brain inflammation in stroke[J]. Lancet Neurol，2019，18（11）：1058-1066.
[3] LAWSON T R，BROWN I E，WESTERKAM D L，et al. Tissue plasminogen activator（rt-PA）in acute ischemic stroke：outcomes associated with ambulation[J]. Restor Neurol Neurosci，2015，33（3）：301-308.
[4] MORALES-RUIZ M，LEE M J，ZÖLLNER S，et al.
Sphingosine 1-phosphate activates Akt，nitric oxide production，and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells[J]. J Biol Chem，2001，276（22）：19672-19677.
[5] LIU J，SUGIMOTO K，CAO Y B，et al. Serum sphingosine 1-phosphate（S1P）：a novel diagnostic biomarker in early acute ischemic stroke[J/OL]. Front Neurol，2020，11：985[2022-12-11]. https://doi.org/10.3389/fneur.2020.00985.
[6] LU S S，SHE M H，ZENG Q，et al. Sphingosine 1-phosphate and its receptors in ischemia[J/OL]. Clin Chim Acta，2021，521：25-33[2022-12-11]. https://doi.org/10.1016/j.cca.2021.06.020.
[7] PITSON S M. Regulation of sphingosine kinase and sphingolipid signaling[J]. Trends Biochem Sci，2011，36（2）：97-107.
[8] OBINATA H，HLA T. Sphingosine 1-phosphate and inflammation[J]. Int Immunol，2019，31（9）：617-625.
[9 MARTIN R，SOSPEDRA M. Sphingosine-1 phosphate and central nervous system[J/OL]. Curr Top Microbiol Immunol，2014，378：149-170[2022-12-11]. https://doi.org/10.1007/978-3-319-05879-57.
[10] OSINDE M，MULLERSHAUSEN F，DEV K K. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors[J]. Neuropharmacology，2007，52（5）：1210-1218.
[11] GAIRE B P，CHOI J W. Sphingosine 1-phosphate receptors in cerebral ischemia[J]. Neuromolecular Med，2021，23（1）：211-223.
[12] ZHANG L，WANG H D. FTY720 in CNS injuries：molecular mechanisms and therapeutic potential[J/OL]. Brain Res Bull，2020，164：75-82[2022-12-11]. https://doi.org/10.1016/j.brainresbull.2020.08.013.
[13] ZHANG S Q，XIAO J，CHEN M，et al. Sphingosine-1-phosphate signaling in ischemic stroke：from bench to bedside and beyond[J/OL]. Front Cell Neurosci，2021，15：781098[2022-12-11]. https://doi.org/10.3389/fncel.2021.781098.
[14] GAIRE B P，BAE Y J，CHOI J W. S1P1 regulates M1/M2 polarization toward brain injury after transient focal cerebral ischemia[J]. Biomol Ther（Seoul），2019，27（6）：522-529.
[15] SAPKOTA A，GAIRE B P，KANG M G，et al. S1P2 contributes to microglial activation and M1 polarization following cerebral ischemia through ERK1/2 and JNK[J/OL]. Sci Rep，2019，9（1）：12106[2022-12-11]. https://doi.org/10.1038/s41598-019-48609-z.
[16] GAIRE B P，SONG M R，CHOI J W. Sphingosine 1-phosphate receptor subtype 3（S1P3）contributes to brain injury after transient focal cerebral ischemia via modulating microglial activation and their M1 polarization[J/OL]. J Neuroinflammation，2018，15（1）：284[2022-12-11]. https://doi.org/10.1186/s12974-018-1323-1
[17] ZHAO Y F，ZHANG X J，CHEN X Y，et al. Neuronal injuries in cerebral infarction and ischemic stroke：from mechanisms to treatment（review）[J/OL]. Int J Mol Med，2022，49（2）：15[2022-12-11]. https://doi.org/10.3892/ijmm.2021.5070.
[18] SUN L L，ZHANG Y X，LIU E，et al. The roles of astrocyte in the brain pathologies following ischemic stroke[J]. Brain Inj，2019，33（6）：712-716.
[19] COLOMBO E，BASSANI C，DE ANGELIS A，et al. Siponimod（BAF312）activates Nrf2 while hampering NFkappaB in human astrocytes，and protects from astrocyte-induced neurodegeneration[J/OL]. Front Immunol，2020，11：635[2022-12-11]. https://doi.org/10.3389/fimmu.2020.00635.
[20] XU S B，LU J N，SHAO A W，et al. Glial cells：role of the immune response in ischemic stroke[J/OL]. Front Immunol，2020，11：294[2022-12-11]. https://doi.org/10.3389/fimmu.2020.00294.
[21] LI Y J，SHI S X，LIU Q，et al. Targeted role for sphingosine-1-phosphate receptor 1 in cerebrovascular integrity and inflammation during acute ischemic stroke[J/OL]. Neurosci Lett，2020，735：135160[2022-12-11]. https://doi.org/10.1016/j.neulet.2020.135160.
[22] JUNG B，OBINATA H，GALVANI S，et al. Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development[J]. Dev Cell，2012，23（3）：600-610.
[23] ICHIJO M，ISHIBASHI S，LI F Y，et al. Sphingosine-1-phosphate receptor-1 selective agonist enhances collateral growth and protects against subsequent stroke[J/OL]. PLoS One，2015，10（9）：e0138029[2022-11-22]. https://doi.org/10.1371/journal.pone.0138029.
[24] IWASAWA E，ISHIBASHI S，SUZUKI M，et al. Sphingosine-1-phosphate receptor 1 activation enhances leptomeningeal collateral development and improves outcome after stroke in mice[J]. J Stroke Cerebrovasc Dis，2018，27（5）：1237-1251.
[25] BLUM A，VAISPAPIR V，KEINAN-BOKER L，et al. Endothelial dysfunction and procoagulant activity in acute ischemic stroke[J]. J Vasc Interv Neurol，2012，5（1）：33-39.
[26] YANAGIDA K，LIU C H，FARACO G，et al. Size-selective opening of the blood-brain barrier by targeting endothelial sphingosine 1-phosphate receptor 1[J]. Proc Natl Acad Sci U S A，2017，114（17）：4531-4536.
[27] SANCHEZ T. Sphingosine-1-phosphate signaling in endothelial disorders[J/OL]. Curr Atheroscler Rep，2016，18（6）：31[2022-12-11]. https://doi.org/10.3892/ijmm.2021.5070.
[28] CAO C C，DAI L，MU J Y，et al. S1PR2 antagonist alleviates oxidative stress-enhanced brain endothelial permeability by attenuating p38 and Erk1/2-dependent cPLA2 phosphorylation[J/OL]. Cell Signal，2019，53：151-161[2022-12-11]. https://doi.org/10.1016/j.cellsig.2018.09.019.
[29] NITZSCHE A，POITTEVIN M，BENARAB A，et al. Endothelial S1P1 signaling counteracts infarct expansion in ischemic stroke[J]. Circ Res，2021，128（3）：363-382.
[30] YANG C J，HAWKINS K E，DORE S，et al. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke[J/OL]. Am J Physiol Cell Physiol，2019，316（2）：C135-C153[2022-12-11]. https://doi.org/10.1152/ajpcell.00136.2018.
[31] PROFACI C P，MUNJI R N，PULIDO R S，et al. The blood-brain barrier in health and disease：important unanswered questions[J/OL]. J Exp Med，2020，217（4）：e20190062[2022-12-11]. https://doi.org/10.1084/jem.20190062.
[32] NAKAGAWA S，ARUGA J. Sphingosine 1-phosphate signaling is involved in impaired blood-brain barrier function in ischemia-reperfusion injury[J]. Mol Neurobiol，2020，57（3）：1594-1606.
[33] XIANG P，CHEW W S，SEOW W L，et al. The S1P2 receptor regulates blood-brain barrier integrity and leukocyte extravasation with implications for neurodegenerative disease[J/OL]. Neurochem Int，2021，146：105018[2022-12-11]. https://doi.org/10.1016/j.neuint.2021.105018.
[34] ZHU Z L，FU Y，TIAN D C，et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke：a pilot trial[J]. Circulation，2015，132（12）：1104-1112.
[35] POIRIER B，BRIAND V，KADEREIT D，et al. A G protein-biased S1P1 agonist，SAR247799，protects endothelial cells without affecting lymphocyte numbers[J/OL]. Sci Signal，2020，13（634）：eaax8050[2022-12-11]. https://doi.org/10.1126/scisignal.aax8050.
[36] HASEGAWA Y，SUZUKI H，SOZEN T，et al. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats[J]. Stroke，2010，41（2）：368-374.
[37] VOGELGESANG A，DOMANSKA G，RUHNAU J，et al. Siponimod（BAF312）treatment reduces brain infiltration but not lesion volume in middle-aged mice in experimental stroke[J]. Stroke，2019，50（5）：1224-1231.
[38] LEE T H，CHENG C N，CHAO H C，et al. Plasma ceramides are associated with outcomes in acute ischemic stroke patients[J/OL]. J Formos Med Assoc，2022，121（1 Pt 1）：43-50[2022-12-11]. https://doi.org/10.1016/j.jfma.2021.01.006.
[39] SCHWEDHELM E，SCHWIEREN L，TIEDT S，et al. Serum sphingosine-1-phosphate levels are associated with severity and outcome in patients with cerebral ischemia[J]. Stroke，2021，52（12）：3901-3907.
[40] CZECH B，PFEILSCHIFTER W，MAZAHERI-OMRANI N，et al. The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia[J]. Biochem Biophys Res Commun，2009，389（2）：251-256.

[1]	谷鸿秋, 杨凯璇, 姜英玉, 杜柯瑾, 饶蓁蓁, 杨昕, 王春娟, 熊云云, 荆京, 李子孝. 缺血性卒中患者卒中复发风险预测模型研究进展及展望 [J]. 中国卒中杂志, 2023, 18(07): 731-739.
[2]	陈思玎, 姜勇, 许喆, 石延枫, 程丝, 谷鸿秋, 王拥军. 多基因风险评分的构建及其在卒中领域的应用[J]. 中国卒中杂志, 2023, 18(07): 741-750.
[3]	王琰, 李佳树, 方瑞乐, 刘改芬, 鞠奕. 伴前庭症状的急性轻型卒中患者6个月焦虑抑郁状态影响因素研究[J]. 中国卒中杂志, 2023, 18(07): 787-792.
[4]	王垚, 秦海强, 王安心, 张晓丽, 左颖婷, 张亚清, 杨波, 于丹丹, 魏娜, 张婧. 卒中患者入院体重指数与3个月预后的关系研究[J]. 中国卒中杂志, 2023, 18(07): 793-798.
[5]	楼敏, 丁晶, 张玉生, 胡波, 万艳, 张珂萌, 费贝尼, 徐炳东, 谭泽锋, 徐安定中国卒中学会中国脑血管病临床管理指南撰写工作委员会楼敏, 丁晶, 张玉生, 胡波, 万艳, 张珂萌, 费贝尼, 徐炳东, 谭泽锋, 徐安定中国卒中学会中国脑血管病临床管理指南撰写工作委员会. 中国脑血管病临床管理指南（第2版）（节选）——第2章卒中组织化管理推荐意见[J]. 中国卒中杂志, 2023, 18(07): 822-828.
[6]	蒲善宇, 潘岳松, 王拥军. INSURE研究解读：吲哚布芬在卒中领域的应用价值[J]. 中国卒中杂志, 2023, 18(06): 633-635.
[7]	程雅琴, 温春娣, 陈晓娜, 陈艳君, 陈星星. 任务导向性训练治疗卒中后患者平衡功能康复效果的meta分析[J]. 中国卒中杂志, 2023, 18(06): 660-669.
[8]	方瑞乐, 冷琦, 鞠奕. 青年与中老年椎动脉夹层伴缺血性卒中患者的危险因素、临床特征及影像表现比较[J]. 中国卒中杂志, 2023, 18(06): 670-676.
[9]	张莺芳, 叶民, 尚羽, 吴明凤. 血清TIMP-3预测恶性大脑中动脉梗死患者死亡的临床价值研究[J]. 中国卒中杂志, 2023, 18(06): 677-683.
[10]	中国卒中学会, 中国卒中学会神经介入分会, 中华预防医学会卒中预防与控制专业委员会介入学组. 急性缺血性卒中血管内治疗中国指南2023[J]. 中国卒中杂志, 2023, 18(06): 684-711.
[11]	逯青丽, 吴松笛. 视网膜动脉阻塞：“视网膜卒中”的认识与挑战[J]. 中国卒中杂志, 2023, 18(06): 712-719.
[12]	樊东升. 阿加曲班联合阿替普酶治疗急性缺血性卒中的可能性：来自中国学者提供的高级别临床循证依据 [J]. 中国卒中杂志, 2023, 18(05): 495-496.
[13]	张亚男, 王赞. 卒中相关睡眠障碍[J]. 中国卒中杂志, 2023, 18(05): 497-501.
[14]	黄真灿, 张亚男, 孙晴晴, 吴小丹, 王赞. 卒中伴阻塞性睡眠呼吸暂停综合征的生物学标志物研究进展[J]. 中国卒中杂志, 2023, 18(05): 514-519.
[15]	贾慧, 王迪, 所芮, 卫馨雅, 朱雨岚. 昼夜节律紊乱增加卒中风险机制的研究进展[J]. 中国卒中杂志, 2023, 18(05): 520-526.